Login
- Titel:
Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer.
- Dokumenttyp:
- Journal Article
- Autor(en):
- Weniger, Maximilian; Moir, John; Damm, Marko; Maggino, Laura; Kordes, Maximilian; Rosendahl, Jonas; Ceyhan, Güralp O; Schorn, Stephan
- Abstract:
- BACKGROUND: Neoadjuvant chemotherapy has become a powerful tool to convert borderline resectable (BRPC) and locally advanced pancreatic cancers (LAPC) into a resectable scenario. However, data analyzing the optimal type of therapy are scarce. In the present multicenter retrospective study, we evaluated the influence of FOLFIRINOX (FFX) and gemcitabine (GEM)-based neoadjuvant therapy on patient prognosis. METHODS: Data on 239 patients from 7 centers across Europe was gathered using an online database. Patients having received their first cycle of chemotherapy for BRPC/LAPC before 06/2017, with a minimum follow-up of 12 months, were included in the intention-to-treat analysis. RESULTS: Patients treated with neoadjuvant FFX (n = 135) or gemcitabine + nab-paclitaxel (GNP) (n = 38) had significantly improved radiological response according to RECIST criteria as compared to single-agent GEM (n = 16), with a partial/complete response of 59.3%, 55.3% and 6.25% respectively (p = 0.001). Treatment with FFX (n = 135) and GNP (n = 38) resulted in higher resection rates compared to GEM (73.3%, 81.6% and 43.8%; p = 0.01 and p = 0.005). Regardless of regimen, patients who were resected had significantly prolonged overall survival compared to non-resected patients (p < 0.01). Complete pathological responses (ypT0 ypN0) were predominantly observed with FFX (p = 0.01). Adjuvant GNP in addition to successful neoadjuvant therapy and surgery resulted in a trend towards improved median survival as compared to postoperative observation (47.0 vs. 30.1 months, p = 0.06). CONCLUSIONS: Representing one of the largest studies published so far, our results reveal that patients with BRPC/LAPC should be offered either FFX or GNP to improve chances of resection and with this also survival.
- Zeitschriftentitel:
- Pancreatology
- Jahr:
- 2020
- Band / Volume:
- 20
- Heft / Issue:
- 6
- Seitenangaben Beitrag:
- 1131-1138
- Volltext / DOI:
- doi:10.1016/j.pan.2020.06.012
- PubMed:
- http://view.ncbi.nlm.nih.gov/pubmed/32739267
- Print-ISSN:
- 1424-3903
- TUM Einrichtung:
- 591; Klinik und Poliklinik für Chirurgie
BibTeX